36
nanotimes
Companies Facts
near perfect multi-language speech recognition with a virtual 15-inch PC display, the Golden-i headset provides immediate hands-free access to nearly any digital information in the world and the ability to remotely control most wireless devices.
http://www.kopin.com
L iquidmetal® Technologies Inc. (OTCBB: LQMT) and The Swatch Group Ltd. (SWX: UHR/UHR N)
have signed an exclusive licensing agreement, allow- ing the Swiss manufacturer to utilize the Liquidmetal alloy technology worldwide.
Within the Swatch Group, the Liquidmetal techno- logy has been used for the first time in 2009 for the Omega Seamaster Planet Ocean, and in 2010 for the Breguet „Reveil musical.“ The present contract will allow The Swatch Group to use the technology exclusively in their entire line of timepieces. The Company reported its financial results for the three months and year ended December 31, 2010. The Company reported revenues of $11.1 million and $33.0 million for the fourth quarter and fiscal year ending December 31, 2010, respectively. Further- more, the Company closed out the quarter and year end with operating income of $4.8 million and $15.7 million, respectively.
Mr. Tom Steipp, President and CEO, commented, “We are pleased with the results of the year and pro- gress made to date in leveraging a growing number of marquee partnerships into a sustainable business model. The most recent announcement on March 10, 2011 with Swatch is just another indicator of the significant interest that we are seeing in the market for Liquidmetal technology.”
http://www.liquidmetal.com
M
agForce Nanotechnologies AG (FSE:MF6), a leader in nanomedicine-based cancer treat-
ment, announced that its sales and marketing team for Germany is in place and commercialization acti- vities are set to begin. With a Commercial Director and four key account managers in place, MagForce will now seek to make its NanoTherm®
therapy
available in clinics across Germany. The company has received EU approval for its medical devices, which use magnetic nanoparticles for the treatment of brain tumors. Through the application of an alter- nating magnetic field, the nanoparticles are activa- ted, and heat is produced from within the tumor.
Solveig Salomon joins the company as European Commercial Director and will lead the commerciali- zation team. She has over twenty years of experience in the pharmaceutical industry, including sales and marketing experience in the area of oncology. Her professional experience includes leading positions held at Sandoz International GmbH, Amgen GmbH, Janssen-Cilag GmbH, and Grünenthal GmbH. The German MagForce Nanotechnologies is a lea- der in nanomedicine-based cancer treatment and focused on the treatment of solid tumors. The company‘s proprietary procedure, NanoTherm®
the-
rapy, enables the targeted treatment of solid tumors through the intratumoral release of heat from ma- gnetic nanoparticles. NanoTherm®
, NanoPlan®
NanoActivator™ are components of the therapy.
http://www.magforce.com
M
iaSolé, the leading manufacturer of copper indium gallium selenide (CIGS) thin-film
photovoltaic solar panels, announced that the U.S. Department of Energy‘s National Renewable Ener- gy Laboratory (NREL) independently confirmed the
, and
11-02/03 :: February / March 2011
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95